OBI
NEUTRALOndine Biomedical Joins CAN Health Network to Advance Infection Prevention
The healthcare company has joined a national network to accelerate the adoption of its infection prevention technology across Canada.
Ondine Biomedical Inc.
8.50GBX
-5.56%
Market Cap
37.67M
Volume
141.94k
100% of avg
P/E Ratio
EPS (TTM)
Beta
0.14
Day Range
8.16p - 8.75p
52 Week Range
5.50p8.50p13.30p
8.50p
Upcoming Events
Mid Q3 2025
Completion of 4-month ICU pilot study
High Impact Event
Early 2026
Potential FDA approval and commercial launch of nasal photodisinfection therapy in the US
High Impact Event
OBI
NEUTRALOndine Biomedical Appoints Interim CFO
The healthcare company has appointed a new interim Chief Financial Officer to support its growth plans.
OBI
NEUTRALOndine Biomedical Announces Full Year Results and Investor Presentation
The life sciences company will publish its 2024 results and host an investor presentation on 15 May 2025.
OBI
NEUTRALOndine Biomedical's Steriwave technology could save UK hospitals £200 million annually
The healthcare technology company's nasal decolonization treatment could generate £200 million in annual savings for UK hospitals by reducing surgical site infections.
OBI
NEUTRALOndine Biomedical Collaborates with Swiss University Hospital on Steriwave Nasal Decolonization Study
The healthcare company has partnered with a Swiss university hospital to evaluate its antimicrobial nasal treatment in a clinical study.
OBI
NEUTRALOndine Biomedical Expands to Switzerland with Steriwave Nasal Decolonization Study
The healthcare company is collaborating with a Swiss hospital to evaluate its Steriwave nasal decolonization technology in a clinical study.
OBI
NEUTRALOndine Biomedical's Steriwave Reduces Surgical Site Infections by 71% at UK NHS Trust
The healthcare company's nasal decolonization technology demonstrated a substantial reduction in surgical site infections at a UK hospital, according to new data.
OBI
NEUTRALOndine Biomedical Announces Board Changes
The healthcare company announces the resignation of a non-executive director.
OBI
GOODOndine Biomedical Advances Steriwave for ICU Market with New Clinical Trial
The life sciences company is launching a clinical trial to evaluate its Steriwave nasal photodisinfection technology for use in intensive care units, a significant market expansion opportunity.
OBI
NEUTRALOndine Biomedical's Steriwave Nasal Photodisinfection Reduces Spine Surgical Site Infections by 78% in Quebec Hospital
The life-sciences company's antimicrobial technology helped a Quebec hospital significantly reduce surgical site infections in spine surgery patients.